Göðüs Hastanesi Dergisi. 2022; 36(1): 34-37 | DOI: 10.14744/IGH.2022.07279

COVID-19 ve Standart Dýþý Tedaviler

Hasan Oktay Emir, Dilek Kazancý
Saðlýk Bilimleri Üniversitesi, Ankara Þehir Hastanesi, Yoðun Bakým Kliniði, Ankara, Türkiye

Koronavirüs hastalýðý (COVID-19), “Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)” tarafýndan oluþturulmaktadýr. Her yaþtan birey SARS-CoV-2 enfeksiyonu ve ciddi hastalýk riski altýndadýr. SARS-CoV-2 enfeksiyonlu hastalar, semptom olmamasýndan kritik hastalýða kadar çeþitli klinik belirtiler yaþayabilir. COVID-19’un standart tedavisi henüz kesin olarak tanýmlanmadý, ancak rehberler tarafýndan önerilen tedavilerin yaný sýra standart dýþý tedaviler de kullanýlmaktadýr. COVID-19’da þimdiye kadar kullanýlan tedaviler arasýnda antiviral grubu ilaçlar, granülosit makrofaj-koloni uyarýcý faktör (GM-CSF) inhibitörleri, interlökin (IL)-1 ve IL-6 inhibitörleri, interferonlar, kinaz inhibitörleri, non-SARS-CoV-2 intravenöz immünglobulin (IVIG); anti-SARS-CoV-2 monoklonal antikorlar mevcuttur. COVID-19’un tedavisinde remdesivir, deksametazon kullanýlmaktadýr. Ayrýca kamostat, favipiravir, molnupiravir gibi antiviral ilaçlarýn çalýþmasý devam etmektedir. COVID-19 ile iliþkili makrofaj aktivasyon sendromunda ise tocilizumab ve sarilumab gibi antisitokin tedaviler kullanýlabilir. IL-1 inhibitörleri, fluvoksamin, IVIG’lar için kesin bir öneri yoktur ve daha çok çalýþmaya ihtiyaç vardýr. Anti-SARS-CoV-2 monoklonal antikorlar tedavi kombinasyon önerileri mevcuttur. Antiviral ilaçlar ve monoklonal antikorlar, konakçý baðýþýklýk tepkisi oluþmadan önce, COVID-19 sýrasýnda erken dönemde en büyük düzelmeyi göstermektedir. Standart dýþý tedavilerin bir kýsmý hala çalýþma aþamasýndadýr ve daha çok çalýþmaya ihtiyaç vardýr.

Anahtar Kelimeler: Anti-SARS-CoV-2 monoklonal antikor, antiviral, COVID-19, deksametazon, intravenöz immünglobulinler.

---

COVID-19 and Non-Standard Treatments

Hasan Oktay Emir, Dilek Kazancý
Department of Intensive Care, University of Health Sciences, Ankara City Hospital, Ankara, Türkiye

COVID-19 infection is caused by the SARS-COV-2 virus. Individuals of all ages are at risk for SARS-COV-2 infection and serious illness. Patients with SARS-COV-2 infection may experience a range of clinical manifestations, from the absence of symptoms to critical illness. The standard treatment of COVID-19 disease has not been defined yet, but non-standard treatments are also used in addition to the treatments recommended by the guidelines. Treatments used so far in COVID-19 disease include antiviral group drugs, granulocyte-macrophage colony-stimulating factor inhibitors, IL-1 and IL-6 inhibitors, interferons, kinase inhibitors, non-SARS-CoV-2 IVIG; and anti-SARS-CoV-2 monoclonal antibodies drugs are available. Remdesivir and dexamethasone are used in the treatment of Covid-19. In addition, the study of antiviral drugs such as camostat, favipiravir, molnupiravir continues. Anticytokine treatments such as tocilizumab and sarilumab can be used in the macrophage activation syndrome associated with COVID-19. There is no definitive recommendation for interleukin-1 inhibitors, fluvoxamine, and intravenous immunoglobulins and more studies are needed. Anti-SARS-COV-2 monoclonal antibodies treatment combination recommendations are available. Antiviral drugs and monoclonal antibodies show the greatest recovery early during COVID-19, before the host immune response occurs. Some of the non-standard treatments are still under study and more studies are needed.

Keywords: Anti SARS-COV-2 monoclonal antibodies, antiviral, COVID-19, dexamethasone, intravenous immunoglobulins.

---

ATIF KOPYALA